Jonathan Lim

GlaxoSmithKline (United States)

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (8)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2020

Collaborators (2)

Floor Backes

The Ohio State University Comprehensive Cancer Center

UNITED STATES

View details

BJ Rimel

Division Chief, Gynecologic Oncology

Fred Hutch Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Lim

Research Interests

Explore related searches

Contact this professor

Articles (8)

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer

Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience.

Initiation of triple therapy maintenance treatment among patients with COPD.

Collaborators (2)

Floor Backes

BJ Rimel

Make your next move.